Atila BCR-ABL Fusion Transcript Detection Kit
The BCR-ABL Fusion Transcript Detection Kit is an in vitro nucleic acid amplification test and enables sensitive and quantitative detection of BCR-Abl fusion transcripts (p210 and p190) in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) individuals expressing BCR-ABL1 fusion transcripts type e13a2, e14a2, and/or e1a2.
This assay applies digital reverse transcription polymerase chain reaction (RT-dPCR) on the QIAcuityTM system or Bio-Rad QX600™ system to quantify fusion transcript levels relative to the ABL1 reference gene and is intended to measure BCR-ABL1 to ABL1, expressed as a log molecular reduction (MR value) from a baseline of 100% on the International Scale.
The test does not differentiate between e13a2 or e14a2 fusion transcripts and does not monitor other rare fusion transcripts resulting from t(9;22). This test is not intended for the diagnosis of CML.
This product is for research use only (RUO). Each kit includes 100 tests.
BCRABL-100Q (QIAcuity™ Digital™ PCR System), BCRABL-100B (QX600™ Droplet Digital™ PCR System)
Atila BCR-ABL Fusion Transcript Detection Kit
The Atila BCR-ABL test is designed to detect the BCR-ABL fusion gene associated with the Philadelphia chromosome, a key molecular marker observed in chronic myeloid leukemia (CML) and certain cases of acute lymphoblastic leukemia (ALL). This assay provides valuable genomic information to support research efforts aimed at characterizing disease mechanisms and evaluating investigational approaches; it is intended for Research Use Only (RUO) and is not validated for clinical diagnostic or therapeutic applications.
